The Fifth Circuit Court of Appeals ruled on July 6, 2026, that Louisiana's Act 358 is valid and does not violate federal law. This decision affects pharmaceutical manufacturers who participate in the Medicaid program and their ability to restrict how discounted drugs are distributed. The court's ruling is significant as it supports state-level regulations aimed at ensuring access to affordable medications for vulnerable communities.
The case, Pharm Research and Manufacturers of America v. Murrill, was filed under docket number 24-30673. It involved several pharmaceutical companies challenging the Louisiana law, which allows covered entities to partner with contract pharmacies to dispense discounted drugs. The manufacturers argued that the law was preempted by federal regulations and violated various constitutional provisions.
The plaintiffs in this case included major pharmaceutical companies such as AbbVie and AstraZeneca, along with the Pharmaceutical Research and Manufacturers of America (PhRMA). They claimed that Act 358 interfered with the federal 340B Drug Pricing Program, which mandates that drug manufacturers provide discounted prices to certain healthcare providers serving low-income patients. The dispute arose after Louisiana enacted Act 358 to counteract restrictions imposed by manufacturers on the use of contract pharmacies, which are crucial for distributing these medications, especially in underserved areas.
The case reached the Fifth Circuit after the U.S. District Court for the Western District of Louisiana ruled in favor of the state, granting summary judgment against the pharmaceutical companies. The manufacturers appealed, asserting that the law was unconstitutional and preempted by federal law.
The Fifth Circuit, led by Judge Don R. Willett, upheld the district court's decision, stating, "Act 358 fits comfortably within [the states’] tradition" of regulating pharmacies and drug distribution. The court emphasized that the law does not disrupt the federal scheme but instead preserves access to medications for the populations Congress intended to protect.
The court found that Act 358 does not conflict with federal law and is not preempted. It stated, "We hold that it is not preempted by federal law and does not violate the Takings Clause, the Contracts Clause, or the Due Process Clause’s prohibition on vagueness." This ruling reinforces the state's authority to regulate drug distribution and ensures that covered entities can continue to provide essential medications to patients.
The impact of this ruling is significant for the pharmaceutical industry and healthcare providers. It allows Louisiana to enforce its law, ensuring that contract pharmacies can dispense discounted drugs without interference from manufacturers. This decision may encourage other states to adopt similar laws, potentially reshaping how pharmaceutical distribution is managed across the country.
Moreover, the ruling sets a precedent for future cases involving state regulations on drug pricing and distribution. It clarifies that states can enact laws that facilitate access to medications without running afoul of federal regulations, as long as those laws do not directly conflict with federal statutes.
Looking ahead, the pharmaceutical companies may consider appealing this decision to the U.S. Supreme Court. However, the court's ruling provides a strong foundation for state-level regulation of drug distribution, which may complicate any attempts to overturn it. As the legal landscape evolves, the implications of this case will likely resonate within the healthcare and pharmaceutical sectors for years to come.